References
  1. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;21;451(7181):914-8.
  2. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:454S–545S.
  3. ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost. 2014;12(10):1580-90.
  4. Hammer Y, Iakobishvili Z, Hasdai D,et al. Guideline-Recommended Therapies and Clinical Outcomes According to the Risk for Recurrent Cardiovascular Events After an Acute Coronary Syndrome. J Am Heart Assoc. 2018;18;7(18):e009885.
  5. Fang MC, Fan D, Sung SH, et al. Treatment and Outcomes of Acute Pulmonary Embolism and Deep Venous Thrombosis: The CVRN VTE Study. Am J Med. 2019;132(12):1450-1457.e1.
  6. Klemen ND, Feingold PL, Hashimoto B, et al. Mortality risk associated with venous thromboembolism: a systematic review and Bayesian meta-analysis. Lancet Haematol. 2020;7(8):e583-e593.
  7. Hao C, Sun M, Wang H, et al. Low molecular weight heparins and their clinical applications. Prog Mol Biol Transl Sci. 2019;163:21-39.
  8. Pineo GF, Hull RD. Heparin and low-molecular-weight heparin in the treatment of venous thromboembolism. Baillieres Clin Haematol. 1998;11(3):621-37.
  9. Xu Y, Wu W, Wang L, et al. Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro. Blood Coagul Fibrinolysis. 2013;24(3):332-8.
  10. Vanholder RC, Camez AA, Veys NM, et al. Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis. Kidney Int. 1994;45(6):1754-9.
  11. Zeymer U, Neuhaus KL. Hirudin and excess bleeding. Implications for future use. Drug Saf. 1995;12(4):234-9.
  12. Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost. 2008;99(5):819-29.
  13. Wu Z, Guo Y, Liu Y, et al. Production technology of recombinant neorudin expressed in E. coli. Beijing Univ. Technol. 2016;(42): 302–308.
  14. LIU Y, YU A, LIU N, et al. Determination of recombinant neorudin in yeast fermentation supernatant by HPLC. Chin Med Biotechnol.2017;12(05):391-396.
  15. Wu Z, Yu A, Zhang C, et al. Preparation of low bleeding anticoagulant fusion protein and its use. US Patent 20100113345A1. PCT No. PCT/CN2007/ 03526. WO 2008/071081 A1. Filed December 11, 2007; issued May 6, 2010.
  16. Zhang C, Yu A, Yuan B, et al. Construction and functional evaluation of hirudin derivatives with low bleeding risk. Thromb Haemost. 2008;99(2):324-30.
  17. Dong X, Meng Z, Gu R, et al. Predicting the metabolic characteristics of neorudin, a novel anticoagulant fusion protein, in patients with deep vein thrombosis. Thromb Res. 2020;194:121-134.
  18. Fareed J, Walenga JM, Iyer L, et al. An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent. Blood Coagul Fibrinolysis. 1991;2(1):135-47.
  19. WANG W, XU X, ZHAO Z, et al. Anti-Thrombus Activity of a Novel Anti-Thrombus Protein EPR- Hirudin. Chin Pharm J. 2013;48(02):111-115.
  20. Camez A. Refludan. First line of treatment for type II heparin-induced thrombopenia. Presse Med. 1998;27 Suppl 2:28-30.
  21. Dong X, Meng Z, Jin J, et al. Development, validation, and clinical pharmacokinetic application of ultra-performance liquid chromatography/tandem mass spectrometry method for simultaneously determining a novel recombinant hirudin derivative (Neorudin) and its active metabolite in human serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;15;1063: 204-213.
  22. Dong X, Gu R, Zhu X, et al. Evaluating prodrug characteristics of a novel anticoagulant fusion protein neorudin, a prodrug targeting release of hirudin variant 2-Lys47 at the thrombosis site, by means of in vitro pharmacokinetics. Eur J Pharm Sci. 2018;30;121:166-177
  23. Monreal M, Costa J, Salva P. Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin. Drugs Aging. 1996;8(3):171-82.
  24. Greinacher A, Völpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999;5-12;99(1):73-80.
  25. Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation. 2001;13;103(10):1479-84.
  26. Wakui M, Fujimori Y, Nakamura S, et al. Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays. J Clin Pathol. 2019;72(12):817-824.
  27. Nowak G. Clinical monitoring of hirudin and direct thrombin inhibitors. Semin Thromb Hemost. 2001;27(5):537-41.
  28. Di N, Squizzato A, Rutjes A, et al. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. Thromb Haemost. 2007;5(2):296-304.
  29. Bates S. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. Semin Thromb Hemost. 2012;38(7):673-82.
  30. Riley R, Gilbert A, Dalton J, et al. Widely Used Types and Clinical Applications of D-Dimer Assay. Lab Med. 2016;47(2):90-102.
  31. Gielen C, Grimbergen J, Klautz R, et al. Fibrinogen reduction and coagulation in cardiac surgery: an investigational study. Blood Coagul Fibrinolysis. 2015;26(6):613-20.
  32. Martini W. Coagulopathy by hypothermia and acidosis: mechanisms of thrombin generation and fibrinogen availability. J Trauma. 2009;67(1):202-8; discussion 208-9.
  33. Despotis G, Skubas N, Goodnough L. Optimal management of bleeding and transfusion in patients undergoing cardiac surgery. Semin Thorac Cardiovasc Surg. 1999;11(2):84-104.
  34. Meyer BH, Luus HG, Müller FO, et al. The pharmacology of recombinant hirudin, a new anticoagulant. S Afr Med J. 1990;78(5):268-70.
  35. Marbet GA. Verstraete M, Kienast J, et al. Clinical pharmacology of intravenously administered recombinant desulfato hirudin (CGP 39393) in healthy volunteers. J Cardiovasc Pharm 1993; 22: 364-72.
  36. Verstraete M, Nurmohamed M. Kienast J, et al. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. J Am Coli Cardiol 1993; 22: 1080-8.
  37. Gómez-Outes A, García-Fuentes M, Suárez-Gea ML. Discovery methods of coagulation-inhibiting drugs. Expert Opin Drug Discov. 2017;12(12):1195-1205.